Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy.
Autor: | van de Donk PP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands., Wind TT; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands., Hooiveld-Noeken JS; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands., van der Veen EL; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands., Glaudemans AWJM; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University Medical Center Groningen, Groningen, The Netherlands., Diepstra A; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Jalving M; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands., de Vries EGE; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands., de Vries EFJ; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University Medical Center Groningen, Groningen, The Netherlands., Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands. g.a.p.hospers@umcg.nl. |
---|---|
Jazyk: | angličtina |
Zdroj: | European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2021 Dec; Vol. 48 (13), pp. 4369-4376. Date of Electronic Publication: 2021 Jun 02. |
DOI: | 10.1007/s00259-021-05407-y |
Abstrakt: | Purpose: Immune checkpoint inhibitors can induce a T cell-mediated anti-tumor immune response in patients with melanoma. Visualizing T cell activity using positron emission tomography (PET) might allow early insight into treatment efficacy. Activated tumor-infiltrating T cells express the high-affinity interleukin-2 receptor (IL-2R). Therefore, we performed a pilot study, using fluorine-18-labeled IL-2 ([ 18 F]FB-IL2 PET), to evaluate whether a treatment-induced immune response can be detected. Methods: Patients with metastatic melanoma received ~ 200 MBq [ 18 F]FB-IL2 intravenously, followed by a PET/CT scan before and during immune checkpoint inhibitor therapy. [ 18 F]FB-IL2 uptake was measured as standardized uptake value in healthy tissues (SUV Results: Baseline [ 18 F]FB-IL2 PET scans were performed in 13 patients. SUV Conclusion: PET imaging of the IL-2R, using [ 18 F]FB-IL2, is safe and feasible. In this small patient group, serial [ 18 F]FB-IL2-PET imaging did not detect a treatment-related immune response. Trial Registration: Clinicaltrials.gov : NCT02922283; EudraCT: 2014-003387.20. (© 2021. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |